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Sustained Ventricular Arrhythmias Among Patients With
Acute Coronary Syndromes With No ST-Segment Elevation
Incidence, Predictors, and Outcomes
Sana M. Al-Khatib, MD, MHS; Christopher B. Granger, MD; Yao Huang, MS;
Kerry L. Lee, PhD; Robert M. Califf, MD; Maarten L. Simoons, MD; Paul W. Armstrong, MD;
Frans Van de Werf, MD; Harvey D. White, DSc; R. John Simes, MD; David J. Moliterno, MD;
Eric J. Topol, MD; Robert A. Harrington, MD
Background—The prognosis of ventricular arrhythmias among patients with non–ST-elevation acute coronary syndromes
is unknown. We studied the incidence, predictors, and outcomes of sustained ventricular arrhythmias in 4 large
randomized trials of such patients.
Methods and Results—We pooled the datasets of the Global Use of Streptokinase and tPA for Occluded Arteries
(GUSTO)-IIb, Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy
(PURSUIT), Platelet IIb/IIIa Antagonism for the Reduction of Acute Coronary Syndrome Events in a Global
Organization Network (PARAGON)-A, and PARAGON-B trials (n26 416). We identified independent predictors of
ventricular fibrillation (VF) and ventricular tachycardia (VT) and compared the 30-day and 6-month mortality rates of
patients who did (n552) and did not (n25 864) develop these arrhythmias during the index hospitalization.
Independent predictors of in-hospital VF included prior hypertension, chronic obstructive pulmonary disease, prior
myocardial infarction, and ST-segment changes at presentation. Except for hypertension, these variables also
independently predicted in-hospital VT. In Cox proportional-hazards modeling, in-hospital VF and VT were
independently associated with 30-day mortality (hazard ratio [HR], 23.2 [95% CI, 18.1 to 29.8] for VF and HR, 7.6
[95% CI, 5.5 to 10.4] for VT) and 6-month mortality (HR, 14.8 [95% CI, 12.1 to 18.3] for VF and HR, 5.0 [95% CI,
3.8 to 6.5] for VT). These differences remained significant after excluding patients with heart failure or cardiogenic
shock and those who died 24 hours after enrollment.
Conclusions—Despite the use of effective therapies for non–ST-elevation acute coronary syndromes, ventricular
arrhythmias in this setting are associated with increased 30-day and 6-month mortality. More effective therapies are
needed to improve the survival of patients with these arrhythmias. (Circulation. 2002;106:309-312.)
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Many studies have investigated the prognostic significanceof ventricular arrhythmias in patients with acute ST-
segment elevation myocardial infarction (MI). The larger studies
done in the thrombolytic era showed that ventricular arrhythmias
complicating ST-segment elevation MI portend higher risks of
short- and long-term mortality1 (Sana M. Al-Khatib, MD,
unpublished data, March 2002). In patients with non–ST-
segment elevation acute coronary syndromes (NSTE-ACS), data
on ventricular arrhythmias are scant. Thus, it is unknown
whether ventricular arrhythmias in this patient population in-
crease the risk of mortality. The purpose of this study was to
examine the incidence, predictors, and outcomes of ventricular
arrhythmias among patients with NSTE-ACS.
Methods
Study Population
For this study, we used a combined database of the Global Use of
Strategies To Open Occluded Arteries in Acute Coronary Syndromes
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(GUSTO-IIb),2 Platelet Glycoprotein IIb/IIIa in Unstable Angina:
Receptor Suppression Using Integrilin Therapy (PURSUIT),3 and
the Platelet IIb/IIIa Antagonism for the Reduction of Acute Coronary
Syndrome Events in a Global Organization Network (PARAGON)-A4
and -B5 studies, 4 randomized clinical trials of platelet IIb/IIIa
inhibitors in non–ST-segment elevation ACS. Details of these trials
have been reported. In brief, these were randomized, double-blind,
multicenter trials that enrolled patients with ischemic chest pain
within 12 to 24 hours of presentation with transient ST-segment
elevation or transient or persistent ST-segment depression or T-wave
inversion. PURSUIT and PARAGON-B enrolled patients without
these electrocardiographic (ECG) changes if they had elevated
troponin or creatine kinase (CK)-MB levels. GUSTO-IIb also en-
rolled patients with persistent ST-segment elevation; these patients
were excluded from the current analysis. Exclusion criteria were
very similar among the trials and included active bleeding, known
coagulopathy, recent surgery or ischemic stroke, prior intracranial
hemorrhage, poorly controlled hypertension, and renal failure.
Treatment
Patients were randomized to receive placebo or a platelet glycopro-
tein IIb/IIIa inhibitor (PURSUIT and PARAGON-A and -B) or
hirudin (GUSTO-IIb). The use of anti-ischemic medications, includ-
ing -blockers, and antiarrhythmic drugs was left to the discretion of
the treating physicians. Prophylactic lidocaine was not routinely
used.
Definitions
Ventricular fibrillation (VF) was defined as irregular undulations of
varying shape and amplitude on the ECG without discrete QRS or T
waves that resulted in prompt hemodynamic compromise requiring
direct-current (DC) cardioversion. Sustained ventricular tachycardia
(VT) was defined as a regular, wide complex tachycardia of
ventricular origin lasting 30 seconds or accompanied by hemody-
namic instability requiring DC cardioversion. Investigators prospec-
tively captured the occurrence of these arrhythmias and reported
them to the data coordinating center for the trial.
End Points
The end points of this analysis were mortality within 30 days and
within 6 months.
Statistical Analysis
All analyses were performed using SAS software. Continuous
variables were summarized as medians with 25th and 75th percen-
tiles, and categorical variables were summarized as frequencies.
Continuous variables were compared using the Kruskal-Wallis test
and categorical variables were compared using the 2 test. Stepwise
logistic multiple regression models were used to identify sets of
factors that together were significantly associated with the occur-
rence of VF and VT. Odds ratios (OR) and 95% CIs are reported for
significant predictors of ventricular arrhythmias. Results were con-
sidered significant at P0.05.
The Cox proportional-hazards model was used to examine the
association between ventricular arrhythmias and 30-day and 6-month
mortality.6 These analyses were performed with the arrhythmia as a
time-dependent covariate. This method credits the survival time of
patients who develop a ventricular arrhythmia to the group without
ventricular arrhythmia until the arrhythmia actually occurs. Associ-
ations with outcomes were established univariably and multivari-
ably. Adjusted hazard ratios (HR) and 95% CIs are reported for
predictors of 30-day and 6-month mortality. Two models have been
developed from the PURSUIT database; one predicts death within 30
days and one predicts death from 30 days to 6 months.7 We adjusted
for the significant predictors of mortality in these models in Cox
modeling used to analyze ventricular arrhythmias.
Results
Patient Characteristics
Of 26 436 patients in the combined database, 20 were
excluded from this analysis because of missing information
about the timing of VF or VT. Of the remaining 26 416
patients, 552 (2.1%) developed ventricular arrhythmias dur-
ing the index hospitalization. The median time to ventricular
arrhythmia was 78.24 hours (25th, 75th percentiles; 16.32,
168.72 hours). The median length of stay in the hospital was
192 hours (25th, 75th percentiles; 120 hours, 288 hours). In
all, 253 patients developed VF alone, 208 developed VT
alone, and 91 developed both VF and VT. Baseline charac-
teristics of these patients are shown in Table 1.
Predictors of Ventricular Arrhythmias
After adjustment for other baseline characteristics, variables
that were significantly associated with VF were prior hyper-
tension, chronic obstructive pulmonary disease, prior myo-
cardial infarction, and the presence of ST-segment changes at
presentation. Except for hypertension, these clinical variables
also significantly predicted VT (Table 2).
In-Hospital and Discharge Medications
Compared with patients without VF or VT, patients who
developed these arrhythmias were less likely to be treated
with -blockers. The use of antiarrhythmic medications was
low in all 4 studies. Data on specific antiarrhythmic medica-
tions were not available in 2 of the 4 combined clinical trials.
In the 2 clinical trials that collected data on specific antiar-
rhythmic medications, amiodarone and sotalol were the most
commonly prescribed antiarrhythmic medications. Few pa-
tients were treated with class I antiarrhythmic medications
(Table 3).
Outcomes
The unadjusted 30-day and 6-month mortality rates were
higher in patients with ventricular arrhythmias (Table 4;
Figure), and this pattern persisted after adjustment for other
prognostic variables. Differences in 30-day mortality and
6-month mortality associated with VF or VT remained
significant after excluding patients with congestive heart
failure or cardiogenic shock and those who died within 24
hours after enrollment (30-day mortality: HR 18.0, 95% CI
12.3 to 26.3 for VF; HR 4.4, 95% CI 2.6 to 7.6 for VT; HR
78.0, 95% CI 49.2 to 123.6 for VT and VF; 6-month
mortality: HR 10.6, 95% CI 8.0 to 14.2 for VF; HR 3.0, 95%
CI 1.9 to 4.4 for VT; HR 25.0, 95% CI 16.5 to 38.0 for VT
and VF). The effect of the study drug on the survival of
patients with VT and VF within each study was examined and
was found to be insignificant.
Discussion
Among patients with NSTE-ACS, the prognosis of sustained
ventricular arrhythmias has been largely uncertain. Our study
is the largest to explore this issue. It suggests that the
in-hospital occurrence of sustained ventricular arrhythmias in
this setting is associated with a significantly increased risk of
mortality. Patients with these arrhythmias had 5- to 15- fold
higher mortality within 6 months. Notably, most of the deaths
occurred during the first 30 days. Thus, to improve the
prognosis of these patients, potentially effective therapies for
NSTE-ACS will have to be started early after admission.
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These findings are in agreement with the results of analy-
ses of the GUSTO-I and GUSTO-III databases (Sana M.
Al-Khatib, MD, unpublished data, March 2002).1 Although
the incidence of ventricular arrhythmias among patients with
NSTE-ACS is lower (2.1%) than that among patients with
ST-segment elevation (up to 10%), these arrhythmias are
associated with significantly increased mortality in either
setting. Notably, in the present study, the absence of conges-
tive heart failure did not eliminate the enormous harmful
effect of these arrhythmias on survival. The best therapy for
patients with these arrhythmias is uncertain, but clearly these
patients require therapies that can improve survival. Impor-
tantly, guidelines for implantation of cardioverter-
defibrillators consider ventricular arrhythmias in acute MI a
contraindication to defibrillator therapy, because such ar-
rhythmias are not believed to affect long-term survival.8 In
light of our findings, these guidelines may need to be
reconsidered.
Patients with ventricular arrhythmias were less likely to
receive -blockers during and after hospitalization in this
study. This may have influenced our findings, given that
-blockers have been shown to reduce mortality after MI.9,10
The association between ventricular arrhythmias and in-
creased mortality in this study, however, is substantial and is
unlikely to become insignificant after adjusting for this
difference.
Some could argue that ventricular arrhythmias are simply a
marker of an increased risk of death and by themselves do not
increase mortality. In this study, adjustment for other factors
known to affect mortality did not eliminate the relationship of










Age, y 67 (60, 74) 66 (58, 74) 68 (55, 73) 65 (55, 72) 0.001
Male 67 74 73 66 0.02
Diabetes mellitus 23 24 38 21 0.001
Hypertension 58 58 64 53 0.02
Prior infarction 46 38 45 32 0.001
Prior bypass surgery 18 14 16 12 0.02
Prior angioplasty 15 11 15 12 0.4
Systolic BP, mm Hg 130 (114, 149) 130 (120, 145) 130 (114, 144) 135 (120, 150) 0.001
Pulse, bpm 77 (66, 89) 73 (64, 84) 76 (66, 92) 73 (64, 84) 0.009
Killip class
I 75 78 86 89 0.001
II 20 21 10 9 0.001
III 4 1 4 1 0.001
IV 1 0 0 1 0.3
Peak CK ratio, IU 2 (1, 6) 1 (1, 4) 2 (0, 5) 1 (0, 2) 0.001
Peak CK-MB ratio, % of control 3 (1, 9) 3 (1, 9) 4 (1, 14) 1 (1, 4) 0.001
Symptom onset to study treatment, h 8 (4, 12) 8 (4, 13) 7 (4, 12) 8 (5, 13) 0.2
BP indicates blood pressure; CK, creatine kinase. Peak CK ratio is the highest CK value divided by upper limit of
normal in a particular hospital and peak CK-MB ratio is the highest CK-MB value divided by the upper limit of normal
in a particular hospital. Data shown are median (25th, 75th percentiles) or percent of group.
TABLE 2. Independent Predictors of In-Hospital Ventricular





Prior chronic obstructive pulmonary disease 2.5 (1.6–4.1) 1.9 (1.1–3.1)
Prior myocardial infarction 1.8 (1.3–2.3) 1.5 (1.1–1.9)
ST depression at presentation 2.5 (1.8–3.3) 1.8 (1.4–2.4)
ST elevation at presentation 1.6 (1.1–2.3) 1.6 (1.2–2.2)
Prior hypertension    1.4 (1.1–1.8)
*The full model for VT also included peak CK ratio, peak CK-MB ratio, age,
and systolic blood pressure, which were significant predictors (with ORs close
to 1) and weight and pulse, which were not. The full model for VF also included
peak CK ratio, peak CK-MB ratio, and systolic blood pressure, which were
significant predictors (with ORs close to 1).











In-hospital 53 56 45 64
Discharged on 44 51 46 60
Angiotensin-converting enzyme inhibitors
In-hospital 48 37 38 30
Discharged on 39 26 50 27
Antiarrhythmic medications
In-hospital 42 33 45 6
Discharged on 22 12 15 4
Data shown are percent of group.
Data not available for PARAGON-B.
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ventricular arrhythmias with higher mortality, suggesting that
these arrhythmias may lead to increased risk.
Predicting the occurrence of these ventricular arrhythmias
is of vast importance. To our knowledge, our study is the first
to identify predictors of such ventricular arrhythmias in this
population. Significant independent predictors of VF were
history of hypertension, history of chronic obstructive pul-
monary disease, prior myocardial infarction, and ST-segment
changes at presentation. Except for hypertension, these clin-
ical variables also were significant predictors of VT. It is not
surprising that ST-segment changes at presentation strongly
predict ventricular arrhythmias, given that these changes may
correlate with a greater degree of ischemia. It is unclear why
chronic obstructive lung disease is a strong predictor of VF
and VT, but chronic hypoxia or acidosis combined with
ischemia could predispose patients to ventricular arrhythmias.
Thus, patients who have these clinical characteristics may
benefit from earlier, more aggressive interventions.
Limitations
The main limitation of this study is that because detailed
information about the postdischarge procedures and medica-
tions was unavailable, we could not explore their relation-
ships with outcomes.
Implications
Mortality of patients with NSTE-ACS and sustained ventricular
arrhythmias is significantly higher than that of NSTE-ACS
patients without these arrhythmias. Therefore, every effort
should be made to identify therapies that would most improve
the outcome of these patients. This would best be accomplished
by randomized clinical trials of the available antiarrhythmic
therapies, including implantable cardioverter-defibrillators.
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TABLE 4. Mortality by Ventricular Arrhythmia
VT Only vs Neither VF Only vs Neither VF and VT vs Neither
Unadjusted Adjusted Unadjusted Adjusted Unadjusted Adjusted
30-Day mortality 11 (8–15) 8 (5–10) 26 (21–33) 23 (18–30) 68 (52–89) 85 (64–114)
6-Month mortality 7 (6–10) 5 (4–7) 15 (12–18) 15 (12–18) 38 (29–49) 37 (29–49)
Data are shown as HR (95% CI).
Kaplan-Meier curves of mortality by ventricular arrhythmia.
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